← Back to Analyst Consensus 
GSK Hold
GSK plc
Current Price —
Implied Upside —
Analysts 34
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jan 6, 2026 | Barclays | downgrade | Equal-Weight → Underweight | $0 | 53% |
| Nov 12, 2024 | Jefferies | downgrade | Buy → Hold | $0 | 52% |
| Oct 31, 2024 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Jul 8, 2024 | UBS | downgrade | Buy → Neutral | $0 | 54% |
| Jul 2, 2024 | Jefferies | maintain | Buy → Buy | $53 | 52% |
| May 30, 2024 | Goldman Sachs | initiate | — → Neutral | $47 | 54% |
| Mar 4, 2024 | Guggenheim | upgrade | Neutral → Buy | $0 | 52% |
| Jan 23, 2024 | Morgan Stanley | initiate | — → Equal-Weight | $44 | 54% |
| Jan 3, 2024 | Jefferies | upgrade | Hold → Buy | $48 | 52% |
Price Target Trend
Jul 26, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days